TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7554760

Group type: EXPERIMENTAL
Intervention: L-arginine (10 g, systemic infusion, n = 5)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: D-arginine (10 g, systemic infusion, n = 3)
Number of subjects: 28

Group type: COMPARATOR
Intervention: L-arginine (40 mumol/l, forearm vascular bed infusion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: D-arginine (40 mumol/l, forearm vascular bed infusion)
Number of subjects: 28
Study: 2371950

Group type: EXPERIMENTAL
Intervention: Physiologic AV filling
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonphysiologic AV filling
Number of subjects: 12
Study: 7015495

Group type: EXPERIMENTAL
Intervention: SP + AC (sulfinpyrazone + acenocoumarol)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo + AC (placebo + acenocoumarol)
Number of subjects: 22
Study: 30815708

Group type: EXPERIMENTAL
Intervention: Memory group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 65
Study: 30543339

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard-of-care treatment beyond disease progression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 0
Study: 26854355

Group type: EXPERIMENTAL
Intervention: 3-module group treatment (cognitive, exposure, skills) for PTSD
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist (WL) condition
Number of subjects: 86
Study: 24331988

Group type: EXPERIMENTAL
Intervention: Electronic apex locator
Number of subjects: 220

Group type: COMPARATOR
Intervention: Digital radiography
Number of subjects: 220
Study: 22919989

Group type: EXPERIMENTAL
Intervention: 0.1% Tacrolimus ointment twice a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.05% Clobetasol propionate ointment once a day
Number of subjects: 21
Study: 20090326

Group type: EXPERIMENTAL
Intervention: Sugar + 1.0% (w/w) CPP‐ACP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sugar + 0.5% (w/w) CPP‐ACP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control sugar (65% sucrose + 33% glucose syrup)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control sugar-free
Number of subjects: 24
Study: 17367769

Group type: EXPERIMENTAL
Intervention: APOC3 S(*)2 allele in female smokers
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: APOC3 S(*)2 allele in female nonsmokers
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: APOC3 polymorphisms in male carriers of less common alleles (‐482T and ‐455C)
Number of subjects: 673

Group type: COMPARATOR
Intervention: APOC3 S(*)1S(*)1 homozygotes with APOE(*)3/3 genotype
Number of subjects: 673
Study: 15741189

Group type: EXPERIMENTAL
Intervention: Training in patient-centred communication for specialists in gastroenterology
Number of subjects: 700
Study: 12006521

Group type: EXPERIMENTAL
Intervention: Pac/FAC (4 cycles of paclitaxel followed by 4 cycles of FAC)
Number of subjects: 524

Group type: COMPARATOR
Intervention: FAC (8 cycles of FAC)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Pac/FAC
Number of subjects: 524

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 524
Study: 9616321

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 3540

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 3540
Study: 7667456

Group type: EXPERIMENTAL
Intervention: Behavioral stress-management program (20 biweekly sessions of progressive muscle relaxation, electromyograph biofeedback-assisted relaxation training, meditation, and hypnosis)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 10
Study: 2495891

Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Triphasic preparation
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Norethindrone
Number of subjects: 1800
Study: 878906

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.27 microgram X kg‐1 X min‐1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.03, 0.06, 0.09 microgram X kg‐1 X min‐1
Number of subjects: 5
Study: 31659794

Group type: EXPERIMENTAL
Intervention: Increasing adiposity
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Tea drinking
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Time spent watching television
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 401
Study: 28139259

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 units daily for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Observation for 12 weeks
Number of subjects: 98
Study: 26083706

Group type: EXPERIMENTAL
Intervention: 12-week skiing intervention
Number of subjects: 0
Study: 23164343

Group type: EXPERIMENTAL
Intervention: Activated platelet-rich plasma (PRP) applied along the fracture line
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no PRP applied)
Number of subjects: 24
Study: 21680622

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 305

Group type: COMPARATOR
Intervention: Routine podiatry care (Control)
Number of subjects: 305
Study: 19327616

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control
Number of subjects: 400
Study: 16555157

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN group, n=20)
Number of subjects: 40
Study: 15592267

Group type: EXPERIMENTAL
Intervention: Persistent defective healing group (17 women with sling erosion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-debridement group (not specified how many)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (7 women with voiding difficulty or symptomatic vaginal prolapse)
Number of subjects: 24
Study: 11742910

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg/d
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg/d
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 11263281

Group type: EXPERIMENTAL
Intervention: Drug-penetration and oral administration of traditional Chinese decoction plus traction
Number of subjects: 91

Group type: COMPARATOR
Intervention: Oral administration of Chinese decoction and traction
Number of subjects: 91
Study: 8644682

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg Fe/d)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Weekly iron supplementation (120 mg Fe/wk)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg Fe/d) in subgroup (n = 45)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Weekly iron supplementation (120 mg Fe/wk) in subgroup (n = 54)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Compliance in daily group
Number of subjects: 139

Group type: COMPARATOR
Intervention: Compliance in weekly group
Number of subjects: 139
Study: 1687121

Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpidem 200 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alpidem (all doses)
Number of subjects: 21
Study: 6347123

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate with low-dose heparin sodium
Number of subjects: 181

Group type: COMPARATOR
Intervention: Low-dose heparin alone
Number of subjects: 181
Study: 30772343

Group type: EXPERIMENTAL
Intervention: Injection of freshly collected autologous adipose tissue
Number of subjects: 21
Study: 28816707

Group type: EXPERIMENTAL
Intervention: Group exercise with brace adjustment twice per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine protocol (Control)
Number of subjects: 30
Study: 27431233

Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine (study 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 50 mg tribendimidine (study 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ≥100 mg tribendimidine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Higher dADT peak concentrations
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Higher adADT peak concentrations
Number of subjects: 68
Study: 24158761

Group type: EXPERIMENTAL
Intervention: Testosterone gel daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22170878

Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation (cTBS) applied over the intact posterior parietal cortex (PPC) of the left hemisphere (LH) for 10 sessions over 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham continuous theta-burst stimulation (sham cTBS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst stimulation (cTBS)
Number of subjects: 10
Study: 20634030

Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural block (CEB)
Number of subjects: 40
Study: 17467430

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (cooling to 32 degrees C and rewarming to 34 degrees C)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (rewarming to 37 degrees C)
Number of subjects: 223
Study: 16248463

Group type: EXPERIMENTAL
Intervention: bFGF intranasally used in one single nasal cavity a week after ESS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment in the other nasal cavity)
Number of subjects: 10
Study: 12092987

Group type: COMPARATOR
Intervention: 1% CHX gel (single professional tooth cleaning)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1% CHX and 1% thymol dental varnish (duplicate applications)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 40% CHX varnish (single application)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1% CHX gel (daily tooth brushing for 2 weeks)
Number of subjects: 128
Study: 9846845

Group type: EXPERIMENTAL
Intervention: Tomato juice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tomato oleoresin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lycopene beadlets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tomato juice and lycopene beadlets
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tomato juice, oleoresin, and lycopene beadlets
Number of subjects: 15
Study: 8620970

Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no methacholine challenge)
Number of subjects: 10
Study: 2486582

Group type: EXPERIMENTAL
Intervention: Barbotage with 0.5% tetracaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Barbotage with 0.5% bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tetracaine without barbotage
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine with barbotage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine without barbotage
Number of subjects: 80
Study: 31661179

Group type: EXPERIMENTAL
Intervention: Genetically instrumented liability to migraine
Number of subjects: 59674

Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 59674

Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 59674
Study: 31250576

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 220

Group type: COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 220
Study: 28463879

Group type: EXPERIMENTAL
Intervention: Same-day ART initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care ART initiation
Number of subjects: 0
Study: 25448776

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 212
Study: 23148565

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 0
Study: 22288298

Group type: EXPERIMENTAL
Intervention: L-arginine 6 g/24-hour
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: L-arginine 12 g/24-hour
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19375091

Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16773028

Group type: EXPERIMENTAL
Intervention: Unsafe sex (defined as at least 1 episode of anal sexual intercourse without a condom with a casual partner during the previous 12 months)
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Poor mental health-related quality of life (HRQL)
Number of subjects: 1117
Study: 15182980

Group type: COMPARATOR
Intervention: Control subjects (healthy age and height matched)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Subjects with posterior pelvic pain
Number of subjects: 14
Study: 11283865

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN + AMA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Interferon alone (IFN)
Number of subjects: 200
Study: 9313664

Group type: EXPERIMENTAL
Intervention: SR-PLA spiral stent
Number of subjects: 45

Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 45
Study: 12959272

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 24
Study: 3102127

Group type: EXPERIMENTAL
Intervention: Suprofen (prostaglandin synthetase inhibitor)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study: 30261896

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 15 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25919120

Group type: EXPERIMENTAL
Intervention: IA+MF
Number of subjects: 14

Group type: COMPARATOR
Intervention: IA alone
Number of subjects: 14
Study: 25746726

Group type: EXPERIMENTAL
Intervention: Selective REM sleep deprivation (awakening at each REM sleep onset)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (same number of NREM sleep awakenings)
Number of subjects: 18
Study: 23570596

Group type: EXPERIMENTAL
Intervention: Half-dose triptorelin (1.875 mg each time)
Number of subjects: 186
Study: 21102204

Group type: COMPARATOR
Intervention: Lateral-entry pinning
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Medial and lateral (crossed) pinning
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 18654731

Group type: EXPERIMENTAL
Intervention: Bladder retraining
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Combination of bladder retraining and anticholinergic drugs
Number of subjects: 500
Study: 16905197

Group type: EXPERIMENTAL
Intervention: Reinforcement schedule with increasing magnitude for consecutive abstinences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reinforcement schedule with reset in reinforcer magnitude for a positive drug test
Number of subjects: 0
Study: 12546342

Group type: EXPERIMENTAL
Intervention: Clemastine (0.68 mg), pseudoephedrine (60 mg), and acetaminophen (1,000 mg)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Pseudoephedrine and acetaminophen
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 10491719

Group type: EXPERIMENTAL
Intervention: One sample of immunological fecal occult blood test (FOBT)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Three samples of immunological fecal occult blood test (FOBT)
Number of subjects: 332
Study: 8894261

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-5 mg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1797490

Group type: EXPERIMENTAL
Intervention: Active gemfibrozil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo gemfibrozil
Number of subjects: 14
Study: 6347746

Group type: EXPERIMENTAL
Intervention: Nimesulide (200 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxyphenbutazone (400 mg/day)
Number of subjects: 100
Study: 29673467

Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention (two 1-hour individualized sessions targeting CHD education and self-management skills)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 121
Study: 27645285

Group type: EXPERIMENTAL
Intervention: INTERVAL trial participants (randomised)
Number of subjects: 48725

Group type: COMPARATOR
Intervention: Non-randomised donors
Number of subjects: 48725
Study: 23406290

Group type: EXPERIMENTAL
Intervention: 3 g amoxicillin one hour pre-operatively
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo capsules 1 hour pre-operatively
Number of subjects: 55
Study: 23265154

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 42
Study: 19460761

Group type: EXPERIMENTAL
Intervention: Combination therapy (anakinra 100 mg/day + pegsunercept 800 microg/kg twice a week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Monotherapy (anakinra 100 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 22
Study: 18550331

Group type: EXPERIMENTAL
Intervention: Intervention arm (Visual Analogue Scale)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation ratio estimation
Number of subjects: 0
Study: 16826487

Group type: EXPERIMENTAL
Intervention: Intradermal skin test with heat-inactivated Lancy-Vaxina
Number of subjects: 83

Group type: COMPARATOR
Intervention: Positive vaccinia-specific interferon-gamma-producing T cell response
Number of subjects: 83

Group type: COMPARATOR
Intervention: Positive neutralizing antibody
Number of subjects: 83
Study: 14526158

Group type: EXPERIMENTAL
Intervention: Acupuncture (manual AP points including Du 20, bilateral Li 4, Ren 3, Ren 4, Ren 6, bilateral Gb 34, bilateral Ub 23, bilateral Lp 6, auriculoacupuncture points)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Acupuncture (manual AP points)
Number of subjects: 57
Study: 10890632

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg afelimomab three times daily over 3 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Afelimomab
Number of subjects: 23
Study: 8750392

Group type: EXPERIMENTAL
Intervention: QMR with temporal content
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (lower temporal complexity)
Number of subjects: 105
Study: 1574014

Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 30
Study: 3922887

Group type: EXPERIMENTAL
Intervention: Commercial diet preparation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial diet preparation 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31273783

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 162

Group type: COMPARATOR
Intervention: l-carnitine
Number of subjects: 162
Study: 29554111

Group type: EXPERIMENTAL
Intervention: Story-Centred Care Intervention Program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 27912954

Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle recommendations based on Iranian traditional medicine (ITM) for 3 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine dietary and lifestyle recommendations for 3 months
Number of subjects: 57
Study: 23932541

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional rotatory surgery
Number of subjects: 80
Study: 22733639

Group type: EXPERIMENTAL
Intervention: Behavioral-based intervention
Number of subjects: 488

Group type: COMPARATOR
Intervention: Information-based intervention
Number of subjects: 488
Study: 19893307

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 17621470

Group type: EXPERIMENTAL
Intervention: Multiple Imputation (MI) methods using SAS, R, and STATA for semi-continuous data
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Multiple Imputation (MI) methods
Number of subjects: 1060
Study: 16253773

Group type: EXPERIMENTAL
Intervention: Amifostine (200 mg/m2 i.v.) administered 15-30 min before each fraction of radiation
Number of subjects: 303

Group type: COMPARATOR
Intervention: RT alone (control)
Number of subjects: 303
Study: 10680028

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 1105
Study: 9253390

Group type: EXPERIMENTAL
Intervention: Prediction models based on data from the first and second visit
Number of subjects: 5

Group type: COMPARATOR
Intervention: Initial costs per randomization
Number of subjects: 5
Study: 28443835

Group type: EXPERIMENTAL
Intervention: 10% boric acid solution
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: EDTA + NaOCl
Number of subjects: 115

Group type: COMPARATOR
Intervention: 2% chlorhexidine
Number of subjects: 115

Group type: COMPARATOR
Intervention: 5.25% NaOCl for 5 min and 17% EDTA for 3 min
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control, no irrigant
Number of subjects: 115

Group type: COMPARATOR
Intervention: 5% boric acid solution at 55°C for 60s
Number of subjects: 115
Study: 2427859

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celiprolol 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celiprolol (all doses)
Number of subjects: 0
Study: 30146932

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1-g capsules daily)
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 15480